. 2021 Jul 19;22(14):7680. doi: 10.3390/ijms22147680

Table 1.

Basal metabolic and morphological parameters in Wistar control (W_WITHOUT) and hereditary hypertriglyceridemic (HHTg_WITHOUT) rats after metformin administration (W_{WITH METFORMIN}), (HHTg_{WITH METFORMIN}).

	W_WITHOUT	W_{WITH METFORMIN}	HHTg_WITHOUT	HHTg_{WITH METFORMIN}	P_STRAIN	P_TREATMENT	P_INTERACTION
Body weight (g)	428 ± 12	432 ± 10	411 ± 9	395 ± 6	<0.01	n.s.	n.s.
LV weight (g/100 g b.w.)	0.131 ± 0.006	0.135 ± 0.005	0.134 ± 0.003	0.143 ± 0.004	n.s.	n.s.	n.s.
EAT weight (g/100 g b.w.)	1.235 ± 0.034	1.196 ± 0.061	1.839 ± 0.038	1.536 ± 0.048 ***	<0.001	<0.001	<0.01
Non-fasting glucose (mmol/L)	6.6 ± 0.2	6.6 ± 0.1	8.6 ± 0.2	8.1 ± 0.2 *	<0.001	n.s.	n.s.
AUC_0-180min (mmol/L)	1268 ± 22	1176 ± 13 **	1476 ± 18	1417 ± 13 *	<0.001	<0.001	n.s.
HOMA-IR	2.1 ± 0.1	1.8 ± 0.1 *	2.7 ± 0.1	2.3 ± 0.1 **	<0.001	<0.001	n.s.
Insulin (nmol/L)	0.279 ± 0.022	0.240 ± 0.036	0.273 ± 0.028	0.238 ± 0.041	n.s.	n.s.	n.s.
Glucagon (pg/mL)	224.61 ± 14.82	212.51 ± 12.33	191.22 ± 13.38	158.84 ± 4.94	<0.01	n.s.	n.s.
Serum TG (mmol/L)	1.56 ± 0.11	1.03 ± 0.08 *	3.45 ± 0.26	2.65 ± 0.20 **	<0.001	<0.001	n.s.
Serum cholesterol (mmol/L)	1.51 ± 0.07	1.37 ± 0.06	1.77 ± 0.03	1.84 ± 0.03	<0.001	n.s.	<0.05
HDL-C (mmol/L)	1.27 ± 0.08	1.15 ± 0.06	0.88 ± 0.03	0.91 ± 0.03	<0.001	n.s.	n.s.
NEFA (mmol/L)	0.496 ± 0.020	0.449 ± 0.022	0.713 ± 0.015	0.646 ± 0.017 *	<0.001	<0.01	n.s.

Two-way ANOVA results: P_STRAIN denotes the significance of W vs. HHTg (strain effects); P_TREATMENT denotes the significance of metformin treatment (treatment effects); P_INTERACTION denotes the significance of metformin treatment in both strains (treatment vs. strain interaction). For multiple comparisons (metformin treatment vs. non-treated controls), Fisher’s LSD post-hoc test was used; * denotes p < 0.05; ** denotes p < 0.01; *** denotes p < 0.001. Data are mean ± SEM; n = 8 for each group. LV—left ventricle; EAT—epididymal adipose tissue.